According to a new industry analysis by Fact.MR, the global autoinjectors market is valued at $59.04 billion in 2023 and is projected to grow at a CAGR of 16% from 2023 to 2033.
An autoinjector is a device equipped with a spring-loaded needle and a pre-filled dose of medication. It automatically activates and delivers an accurate dose when inserted into the body. These devices are widely used for migraine treatment, medical emergencies, and self-administration of epinephrine to manage anaphylaxis.
Autoinjectors offer numerous benefits, such as reducing needle-related anxiety, minimizing the risk of accidental needle sticks, ensuring consistent dosage, and enhancing treatment efficacy. Anaphylaxis is a severe, potentially life-threatening allergic reaction to foods, medications, latex, and insect stings.
Download a Free Sample Copy of this Report - https://www.factmr.com/connectus/sample?flag=S&rep_id=8346
Rheumatoid arthritis (RA) is an autoimmune disease in which the body's immune system attacks the joints, causing inflammation of the synovium and consequent pain and swelling in the joints and surrounding tissues. Arthritis primarily affects the elderly and is more common in women than in males.
There are currently 727 million people in the globe who are 65 or older, and by 2050, this number is expected to more than quadruple, according to the United Nations globe Population Prospects 2020 study.
As arthritis becomes more prevalent among the elderly, there is a growing demand for autoinjectors. Autoinjector sales are also being driven by the rise in chronic conditions like diabetes and cancer.
Country-Wise Analysis
The demand for autoinjectors in the United States is expected to grow rapidly during the forecast period, driven by factors such as the increasing prevalence of chronic diseases like diabetes and cancer, along with a high rate of adoption of advanced products.
According to Globocon 2020, the United States saw 612,390 cancer-related deaths and 2,281,658 new cancer diagnoses in 2020. Breast cancer had the highest incidence, with 253,465 cases, followed by lung cancer (227,875), prostate cancer (209,512), and colon cancer (101,809).
Conditions like diabetes and anaphylaxis have also seen significant growth in the U.S. The Centers for Disease Control and Prevention (CDC) reports that over 37.3 million Americans live with diabetes, many of whom rely on insulin injections for blood sugar management. Anaphylaxis, a potentially fatal allergic reaction, affects approximately one in 50 individuals, according to the Asthma and Allergy Foundation of America (AAFA).
Furthermore, the U.S. market is benefiting from technological advancements, the entry of new competitors, and the rapid introduction of innovative products.
Competitive Landscape
Key players in the autoinjectors market are focusing on advanced home-use autoinjectors, needle-free devices, and therapies to expand their client base and revenue. They are also utilizing strategies like mergers, collaborations, partnerships, and regional expansions.
Fact.MR’s report highlights strategies such as local supply chains, product standards, and quality control to boost market share.
In May 2022, Jabil Healthcare launched the Qfinity autoinjector platform for cost-effective, self-administered subcutaneous drug delivery. That same month, Stevanato Group S.p.A. secured an exclusive deal with Owen Mumford Ltd. for its Aidaptus auto-injector.
Key Segments of Autoinjectors Industry Research
-
By Disease:
- Rheumatoid Arthritis
- Anaphylaxis
- Multiple Sclerosis
- Cardiovascular Disorders
- Diabetes
-
By Type:
- Disposable Autoinjectors
- Reusable Autoinjectors
-
By Route of Administration:
- Subcutaneous
- Intramuscular
-
By Type of Molecule:
- Monoclonal Antibodies
- Peptides, Proteins
- Small Molecules
-
By End User:
- Home Care Settings
- Hospitals & Clinics
- Ambulatory Care Settings
-
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- MEA
๐๐จ๐ง๐ญ๐๐๐ญ:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com
Comments
0 comment